RNA therapies present significant opportunities in targeting a broad range of diseases through various innovative approaches, including antisense oligonucleotides, siRNAs, mRNA vaccines, and aptamers.
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
Northwestern Medicine scientists have discovered that a specific long non-coding RNA activates oncogenic signaling pathways ...
Parkinson’s disease (PD) is entering a pivotal phase. For decades, treatment has centred on dopamine replacement to manage ...
Biogen Inc. BIIB on Tuesday entered into an agreement with Alloy Therapeutics Inc. to accelerate the development of antisense ...
Alloy Therapeutics inks multi-target collaboration and license pact with Biogen for use of Alloy’s AntiClastic ASO platform: Boston, Massachusetts Wednesday, April 8, 2026, 16:0 ...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
Columbia's Silence ALS program is testing spinal antisense therapy in a high‑risk patient; early EMG tests normalized.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
The lack of effect on different measures of coronary plaque reinforce the need for a large CV outcomes trial in these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results